Skip to main content
. 2020 Jun 25;27(2):1073274820935843. doi: 10.1177/1073274820935843

Figure 2.

Figure 2.

Kaplan-Meier curves of the time to progression between TACL-ECF and sorafenib treatment groups in total patients (A), CPC A (B), CPC B (C), BCLC B (D), and BCLC C (E). BCLC indicates Barcelona Clinic Liver Cancer; CPC, Child-Pugh class; ECF, epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil; TACL, transarterial chemolipiodolization.